Nov. 12 at 6:24 PM
$DOX This is my checklist: Mainz Biomed beats on AA ~82% (vs 43%/13%) and holds ~97/97 CRC with ~100% HGD. Maxim primed institutions, GARPS primed clinicians, MEDICA closes distribution and lab pilots in EU/UK/CH. Hit two deals and the
$14 price target becomes reasonable, not optimistic.